Safety study of MER511 in adults with Graves' disease
Tests how well adults with Graves' disease tolerate MER511 and what side effects occur.
Key facts
- Who runs it
- Merida Biosciences
- Where
- Boston, Columbus, DeSoto, Hollywood, Miami, Morehead City, Philadelphia, Rochester, Torrance, Webster, and Wesley Chapel, United StatesSee the 11 sitesAlso in 1 other country, 9 sites
- Trial code
- Registry title
- NEXUS Study: A Study to Test Single and Multiple Doses of MER511 Given to Adults With Graves' Disease
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 100 people, planned
- Started
- 19 Dec 2025
- Expected to end
- 24 Jul 2028
- Type of study
- Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- MER511 (IV)
- Placebo comparator (IV)
- MER511 (SC)
- Placebo comparator (SC)
- MER511 (SC) for MAD
- Placebo comparator (SC) for MAD
- Record updated
- 29 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Graves' disease who take a steady dose of an antithyroid drug. It tests the safety of MER511 given into a vein or under the skin, compared with placebo.
- Age
- 18 to 65 years
- Sex
- All sexes
- Disease stage
- A documented diagnosis of Graves' disease. People with active or chronic moderate-to-severe thyroid eye disease (TED) cannot join.
- Earlier treatment
- Must be on a stable dose of an antithyroid drug (ATD). No radioactive iodine (RAI) therapy within 12 months. No levothyroxine, thyroid extract or T3 within 6 weeks. No TED treatment within 3 months.
- Biomarker or test result
- Total IgG level must not be below 700 mg/dL. Body weight at least 50 kg (110 lb) and BMI 18.0-35.0 kg/m2.
Main reasons for not taking part
- Thyroid fully removed by surgery, thyroid storm, or overactive thyroid not caused by Graves' disease
- Serious blood or liver problems caused by earlier antithyroid drugs, or any history of liver disease
- Likely to need RAI therapy or thyroid surgery during the study
- Pregnant, breastfeeding or planning pregnancy
- HIV, hepatitis B or active hepatitis C infection, or reduced kidney function (eGFR <75 mL/min/1.73 m2)
The registry criteria, word for word
Show all 34 criteriaShow less
Who can take part
- Adults 18 to 65 years of age, inclusive, at the time of signing the ICF
- Documented GD diagnosis,
- Receiving stable dose of ATD (Antithyroid drug)
- Body weight at least 50 kg (110 lb) and body mass index (BMI) 18.0-35.0 kg/m2, inclusive
- Women of childbearing potential must agree to use highly effective contraceptive methods
- Men with partners of childbearing potential or who are pregnant must agree to use a condom or strict abstinence
- Signed informed consent to participate in the study
- Willingness and ability, in the opinion of the investigator, to comply with protocol requirements and restrictions (eg, dosing, schedule of assessments)
Who cannot take part
- History of:; total thyroidectomy; History of hyperthyroidism not caused by GD (eg, toxic adenoma, toxic multinodular goiter); History of thyroid storm; History of agranulocytosis, anemia, leukopenia, thrombocytopenia, vasculitis, or liver toxicity due to prior ATD therapy Treatment with RAI therapy within 12 months prior to Screening
- Likely to require definitive treatment for GD (RAI therapy or thyroidectomy) during the study, based on GD history and anticipated prognosis
- Use of levothyroxine, desiccated thyroid extract, or T3 at any dose within 6 weeks prior to Screening
- History of TED-directed medical treatment (including IV/oral steroids, immunosuppressants, or teprotumumab), surgical treatment, and/or orbital radiation within 3 months prior to Screening, or per required prohibited concomitant therapy washout criteria in the protocol (whichever is longer)
- Major surgery or use of iodinated contrast within 3 months prior to planned IMP dosing
- Treatment with prohibited medications prior to planned IMP dosing or likely to require prohibited concomitant therapy during the study
- Live vaccine(s) or mRNA vaccine(s) within 1 month prior to IMP dosing, or plans to receive such vaccines during the study
- Treatment with any investigational drug within within 3 months or 5 half-lives (whichever is longer) prior to enrollment
- Positive drug screen or positive test for alcohol
- Donated more than 500 mL of blood in the 2 months prior to signing the ICF
- Current enrollment or past participation within 3 months or 5 half-lives (whichever is longer) prior to signing the ICF in any other clinical trial involving an IMP
- Active systemic autoimmune disease requiring treatment that causes undue risk in the opinion of the investigator
- History of cardiovascular, respiratory, renal, gastrointestinal, endocrinological (other than GD), hematological, immunodeficiency, or neurological disorders that may constitute a risk when taking the IMP or interfere with data interpretation
- History of liver disease
- Positive result for HIV antibody, HBsAg, or hepatitis C antibody with detectable viral RNA levels at Screening
- Heart rate <45 bpm or >100 bpm
- Any other conditions that, in the opinion of the investigator or the sponsor, could interfere with participation in or completion of the study
- Total IgG level <700 mg/dL at Screening
- Any of the following at Screening (confirmed by single repeat measurement, if deemed necessary):; ALT or AST >1.5 × ULN; Total bilirubin >1.5 × ULN
- Estimated glomerular filtration rate (eGFR) <75 mL/min/1.73 m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation
- Current active or chronic moderate-to-severe TED per EUropean Group On Graves' Orbitopathy (EUGOGO) criteria as judged by the investigator at Screening
- Pregnant, breastfeeding, or planning to become pregnant during the study
- 12-lead ECG demonstrating any of the following at Screening:; QTcF interval >450 ms; QRS interval >120 ms; PR interval >220 ms
- Blood pressure measurements demonstrating any of the following at Screening:; Systolic blood pressure ≥140 mmHg; Diastolic blood pressure ≥90 mmHg
- Refusal to adhere to lifestyle considerations as defined in the protocol
- Employee of the investigator, clinic, or sponsor with direct involvement in the proposed study or other studies under the direction of the investigator or clinic, as well as family members of the employee or investigator
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
Also in 1 other country, 9 sites
- Boston, MassachusettsHospital not named in the registryContact: Principal InvestigatorTaking people
- Columbus, OhioHospital not named in the registryContact: Principal InvestigatorTaking people
- DeSoto, TexasHospital not named in the registryContact: Principal InvestigatorTaking people
- Hollywood, FloridaHospital not named in the registryContact: Principal InvestigatorTaking people
- Miami, FloridaHospital not named in the registryContact: Principal InvestigatorTaking people
- Morehead City, North CarolinaHospital not named in the registryContact: Principal InvestigatorTaking people
- Philadelphia, PennsylvaniaHospital not named in the registryContact: Principal InvestigatorTaking people
- Rochester, MinnesotaHospital not named in the registryContact: Principal InvestigatorTaking people
- Torrance, CaliforniaHospital not named in the registryContact: Principal InvestigatorTaking people
- Webster, TexasHospital not named in the registryContact: Principal InvestigatorTaking people
- Wesley Chapel, FloridaHospital not named in the registryContact: Principal InvestigatorTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate how well MER511 is tolerated and what side effects may occur in adults who have Graves' disease. The study drug will be administered either intravenously (into a vein in the arm) or subcutaneously (under the skin).
Read full original descriptionShow less
Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
The 6 groups in the trial
- Part A (SAD) MER511 IVTreatment being tested
For Cohorts 1-7 , each cohort participant will receive a single ascending dose of MER511 via IV administration on Day 1
Treatment: MER511 (IV)
- Part A (SAD) placebo IVPlacebo, for comparison
For Cohorts 1-7, each cohort participant will receive a single dose of placebo via IV administration on Day 1
Treatment: Placebo comparator (IV)
- Part A (SAD) MER511 SCTreatment being tested
For Cohort 8, participants will receive a single dose of MER511 (determined from Cohort 1-7) via SC administration on Day 1
Treatment: MER511 (SC)
- Part A (SAD) placebo SCPlacebo, for comparison
For Cohort 8, participants will receive a single dose of placebo (determined from Cohort 1-7) via SC administration on Day 1
Treatment: Placebo comparator (SC)
- Part B (MAD) MER511 SCTreatment being tested
Up to 3 cohorts of participants will receive multiple ascending doses of MER511 via SC administration assigned for their cohort on Day 1 and Day 29
Treatment: MER511 (SC) for MAD
- - Part B (MAD) placebo SCPlacebo, for comparison
Up to 3 cohorts of participants will receive multiple doses of placebo via SC administration assigned for their cohort on Day 1 and Day 29
Treatment: Placebo comparator (SC) for MAD
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase 1, First-in-Human, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous Administration of MER511 in Adults With Graves' Disease
- Plain-language title
- Safety study of MER511 in adults with Graves' diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07305818, who can take part
- Record updated
- 29 October 2026